June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
IRay™ treatment of Polypoidal Choroidal Vasculopathy: a Pilot Study
Author Affiliations & Notes
  • Ugo Introini
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Giacinto Triolo
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Giuseppe Casalino
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Francesco Bandello
    Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Footnotes
    Commercial Relationships Ugo Introini, None; Giacinto Triolo, None; Giuseppe Casalino, None; Francesco Bandello, ALLERGAN Inc. (S), NOVARTIS PHARMACEUTICALS CORPORATION (S), FARMILA-THEA (S), BAYER SCHERING PHARMA (S), PFIZER Inc. (S), ALCON Inc. (S), BAUSCH AND LOMB (S), GENENTECH Inc. (S), ALIMERA SCIENCES Inc. (S), SANOFI AVENTIS (S), THROMBOGENICS (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3786. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ugo Introini, Giacinto Triolo, Giuseppe Casalino, Francesco Bandello; IRay™ treatment of Polypoidal Choroidal Vasculopathy: a Pilot Study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3786. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the efficacy and safety of stereotactic radiotherapy (IRay™, Oraya) combined with Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV) treatment.

Methods: Interventional twelve-month Pilot Study. Ten eyes of 10 patients with AMD and PCV were included. The polypoidal complex should be no closer to the optic disk than 3 mm, BCVA between 25 and 75 ETDRS letters, and axial length between 20 mm and 26 mm. At baseline, all the eyes received an intravitreal injection of Ranibizumab, followed by a single dose of 16 Gy delivered on the macular area with the IRay™ System. During monthly follow-up visits, further Ranibizumab injections were given PRN. Primary Outcomes were BCVA and Central Retinal Thickness (CRT) changes. Secondary Outcomes were mean injection number and PCV changes by means of ICGA.

Results: At month six, mean BCVA improved from 62.8±11.6 to 66.8±13.7 ETDRS letters. Mean CRT decreased from 358.3±88.3 µm to 195.5±56 µm. Mean additional intravitreal injections were 1.9. The PCV aneurysmal bulge component was obliterated in all cases when included in the irradiation spot. No local or systemic adverse events occurred.

Conclusions: Our preliminary data on combined Ranibizumab and stereotactic X-ray therapy of PCV showed a mean BCVA improvement, a mean CRT decrease and aneurismal component closure. The latest results will being shown first at ARVO.

Keywords: 412 age-related macular degeneration • 671 radiation therapy • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×